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Background and aim: Mortality rate is high in patients with chronic obstructive pulmonary 
disease (COPD). Our aim was to investigate long-term mortality and associated risk factors in 
COPD patients previously hospitalized for a COPD exacerbation.
Methods: A total of 256 patients from the Nordic countries were followed for 8.7 ± 0.4 years 
after the index hospitalization in 2000–2001. Prior to discharge, the St George’s Respiratory 
Questionnaire was administered and data on therapy and comorbidities were obtained. 
Information on long-term mortality was obtained from national registries in each of the Nordic 
countries.
Results: In total, 202 patients (79%) died during the follow up period, whereas 54 (21%) were 
still alive. Primary cause of death was respiratory (n = 116), cardiovascular (n = 43), malignancy 
(n = 28), other (n = 10), or unknown (n = 5). Mortality was related to older age, with a hazard 
risk ratio (HRR) of 1.75 per 10 years, lower forced expiratory volume in 1 second (FEV
1
) 
(HRR 0.80), body mass index (BMI) ,20 kg/m2 (HRR 3.21), and diabetes (HRR 3.02). Older 
age, lower BMI, and diabetes were related to both respiratory and cardiovascular mortality. An 
association was also found between lower FEV
1
 and respiratory mortality, whereas mortality 
was not significantly associated with therapy, anxiety, or depression.
Conclusion: Almost four out of five patients died within 9 years following an admission for 
COPD exacerbation. Increased mortality was associated with older age, lower lung function, 
low BMI, and diabetes, and these factors should be taken into account when making clinical 
decisions about patients who have been admitted to hospital for a COPD exacerbation.
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Introduction
More advanced chronic obstructive pulmonary disease (COPD) is associated with 
recurrent exacerbations characterized by acute worsening of dyspnea, cough, and 
sputum production.1 Previous studies on mortality following hospitalization for an 
acute exacerbation of COPD (AECOPD) have shown a short-term mortality of up 
to 49%.2–4 The 3-year mortality after hospitalization for AECOPD has been reported 
to be up to 54%.5–7 A large study of outpatients suffering from COPD observed a 
3-year mortality of only 14.3%.8 Studies on patients followed after AECOPD found 
the 5-year mortality to be 73%–76%.9,10
Patients previously hospitalized for AECOPD represent a high-risk group, and 
identification of, hopefully modifiable, risk factors are therefore of utmost importance. 
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Previous studies of this high-risk group of patients have 
identified increasing age, signs of respiratory failure,2 
maintenance use of systemic steroids,2 impaired health 
status, single status, depression, comorbidity, and a history 
of previous hospitalizations for AECOPD as risk factors 
for mortality.11 The frequency of exacerbations has also 
been shown to have an impact on overall mortality after a 
follow-up period of 5 years.12 Based on a 2-year follow-up 
study of our COPD cohort, we have previously reported 
that patients with diabetes hospitalized for AECOPD 
had an increased mortality rate compared to nondiabetic 
patients with AECOPD. To our knowledge, this was the 
first study to show this relationship.4 Our previous study 
also showed that cardiovascular comorbidity and a high 
depression score increased the risk of mortality in patients 
with an impaired health status.4 In order to expand further 
on these observations, and add to our present knowledge, 
we considered it important to evaluate long-term mortality 
in our cohort of Nordic COPD patients.
The primary aim of the present study has been to 
investigate long-term mortality (.8 years) in COPD patients 
previously hospitalized for an acute exacerbation of the 
disease, and secondly to identify risk factors for mortality.
Methods
In earlier publications, we have described in detail our 
prospective Nordic study of patients hospitalized for 
an AECOPD at five university hospitals in each of the 
Nordic countries.4,13,14 The departments included were: 
the Department of Respiratory Medicine and Allergology, 
Akademiska Sjukhuset, Uppsala, Sweden; the Department 
of Respiratory Medicine, Vifilstadir University Hospital, 
Gardabaer, Iceland; and the Department of Respiratory 
Medicine, Hvidovre Hospital, Copenhagen, Denmark. 
Approval from the ethics committee was obtained at each 
center. Briefly, patients were enrolled consecutively during 
an admission for a COPD exacerbation in 2000–2001, and 
COPD was defined according to the Global Initiative for 
Chronic Obstructive Pulmonary Disease (GOLD) guidelines.1 
The principal investigator at each center reviewed all case 
records and written informed consent was obtained from all 
participating subjects.
The case record forms used at all centers included the 
following information: smoking status, family status, height, 
body weight, spirometry results including predicted value 
for forced expiratory volume in 1 second (FEV
1
),15 COPD 
severity according to GOLD,1 health status (assessed by St 
George’s Respiratory Questionnaire [SGRQ]16), anxiety and 
depression (assessed by the Hospital Anxiety and Depression 
Scale17), comorbidities (including diabetes and cardiovascular 
disease), and medication for COPD (including long-term 
oxygen therapy). The last patient was enrolled in the present 
study prior to the marketing of tiotropium in the Nordic 
countries.
Approximately 9 years after the index hospitalization for 
COPD, information regarding vital status and causes of death 
was obtained from the national registries in each country. 
The primary cause of death was divided into the following 
categories: (1) respiratory causes including: exacerbation of 
COPD (ICD-10 DJ440/DJ441), respiratory failure (DJ96x), 
and lower respiratory tract infection (DJ12 to DJ18), (2) cardio-
vascular causes, including myocardial infarction (DI21), 
left ventricular failure (DI50), stroke (DI61 to DI63), and 
pulmonary embolism (DI26), (3) Malignancy, including lung 
cancer (DC34), and breast cancer (DC50), and (4) Other causes, 
including septic shock (DR57) and aspiration (DJ69).
Statistics
Analyses were carried out using Stata software (v 9.0; Stata 
Corporation, College Station, TX). The chi-square test and 
the unpaired t-test were used when comparing baseline 
characteristics of patients that had died and survived, 
respectively, during the study period. The relationship 
between survival time and patient characteristics was 
determined with Kaplan–Meier survival analysis and Cox 
regression. Multivariate analyses were carried out with the 
Cox model. The analyzed independent variables were chosen 
based on statistical significance in the bivariate analyses 
(P , 0.10) and on clinical relevance. Age, FEV
1
, and health 
status were entered as continuous variables, while sex, 
smoking status, comorbidity, and treatment were entered as 
categorical variables. Variables related to pharmacological 
treatment were entered into the model as described 
previously.4 Interaction analyses were done looking at the 
possible differences in independent risk factors for mortality 
in relation to GOLD stage, sex, and smoking status. A P-value 
of ,0.05 was considered statistically significant.
Results
A total of 256 patients (110 women and 146 men) from 
Copenhagen (n = 88), Reykjavik n = 81, and Uppsala 
(n = 87) previously hospitalized for a COPD exacerbation 
in the years 2000–2001 were included in the analyses. Mean 
follow-up for the patient cohort time was 8.7 ± 0.4 years. 
At the end of the follow-up, 202 patients (79%) had died, 
whereas 54 (21%) patients were still alive. Primary cause 
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of death was respiratory (n = 116), cardiovascular (n = 43), 
malignancy (n = 28), other (n = 10), while no information 
was available for five patients (Figure 1). The baseline 
characteristics of the patients who were either dead or alive 
at the time of follow-up are presented in Table 1. In general, 
patients who died during follow-up were older and had lower 
BMI. They also had lower lung function and higher GOLD 
stages at the time of discharge from hospital in 2000–2001. 
There were no other significant associations including 
treatment, anxiety, and depression. As expected, the highest 
prevalence of diabetes (24%) was found in the obese group 
(BMI . 30 kg/m2),  followed by the overweight group (BMI 
25–30 kg/m2) (13%). The prevalence of diabetes in those 
with a BMI , 25 kg/m2 was 6%.
In the multivariable analyses (Table 2), mortality was 
related to older age, lower lung function, lower BMI, and 
diabetes. Older age, lower BMI, and diabetes were related 
to both respiratory and cardiovascular mortality. Respiratory 
mortality was related to lower lung function. There was no 
association between mortality and treatment, anxiety, or 
depression (data not shown).
A significant relationship between GOLD stages and 
survival was found (Figure 2). The proportion of respiratory 
death increased and the proportion of cardiovascular deaths 
decreased with increasing COPD severity (Figure 3). There 
were no significant differences in the relationship between 
determinants for mortality between the different GOLD 
stages (data not shown).
Women were more likely than men to have cancer 
as recorded cause of death (Figure 4). Diabetes was 
more strongly related to all-cause mortality in men 
than in women (odds ratio [OR], 4.77; 95% conf i-
dence interval [CI]: 1.82–12.5, versus OR, 1.79; 95% 
CI: 0.82–3.89; P = 0.03). No interaction was found between 
risk factors for mortality and smoking.
Discussion
Nine years after hospitalization for an AECOPD, the majority 
(79%) of the patients had died, primarily from respiratory 
(57%) and cardiovascular (21%) causes. Higher age, lower 
BMI, lower FEV
1
, and diabetes were the major risk factors 
for mortality.
Information is available on long-term mortality in patients 
with COPD after hospitalization for AECOPD from other 
studies. A study from Italy followed 288 patients, mean FEV
1
 
46%, for 6 years after hospitalization for COPD, and observed 
a 19% mortality rate.18 A study on patients with AECOPD 
Cause of death
Respiratory
Cardiovascular
Malignancy
Other
Unknown
Figure 1 Distribution of causes of death in patients previously admitted to hospital 
for an acute exacerbation in chronic obstructive pulmonary disease.
Table 1 Baseline characteristics for patients (n = 256) with a 
previous hospital admission for COPD according to vital status at 
the time of follow-up (n, % or mean ± SD)
Alive 
n = 54
Dead 
n = 202
P-value*
Men (%) 20 (37) 89 (44) 0.32
Age (years) 63 ± 10 71 ± 9 ,0.0001*
Current smoker (%) 18 (33) 46 (23) 0.12
Pack years 36 ± 21 41 ± 24 0.19
FEV1  % pred 47 ± 19 36 ± 18 0.0001*
GOLD stages (%) ,0.0001*
 Stage 1–2 25 (47) 10 (18)
 Stage 3 16 (29) 61 (30)
 Stage 4 13 (24) 105 (52)
BMI 26 ± 6 24 ± 5 0.004*
BMI groups (%) 0.02
 ,20 5 (9) 42 (21)
 20–25 18 (33) 91 (45)
 25–30 23 (42) 44 (22)
 .30 9 (16) 22 (11)
College education (%) 14 (26) 48(24) 0.83
Living alone (%) 29 (54) 125 (62) 0.28
Cardiovascular disease (%) 20 (37) 97 (48) 0.15
Diabetes (%) 4 (7.4) 22 (11) 0.45
Anxiety (%) 7 (13) 42 (21) 0.21
Depression (%) 5 (10) (9) 0.80
SGRQ
 Total 51 ± 18 55 ± 17 0.10
 Symptom 60 ± 18 63 ± 21 0.44
 Activity 59 ± 25 66 ± 21 0.046*
 Impact 41 ± 19 44 ± 18 0.31
LABA and/or ICS (%) 0.23
 None 7 (13) 44 (22)
 LABA alone 6 (11) 22 (11)
 ICS alone 12 (22) 56 (28)
 LABA and ICS 29 (53) 77 (38)
Long term oxygen treatment (%) 7 (13) 50 (25) 0.06
Note: *Statistically significant.
Abbreviations: FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative 
for Chronic Obstructive Lung Disease; BMI, body mass index; SGRQ, St George’s 
Respiratory Questionnaire; LABA, long-acting β2-agonists; ICS, inhaled corticosteroids.
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severe enough to be treated in intensive care unit found the 
5-year mortality to be 76%.9 A Danish study found overall 
5-year mortality to be 73% after treatment for AECOPD 
and it was higher in those that had been hospitalized.19 
A population-based study of 20,571 participants with a 
10-year median follow-up showed that hospitalization for 
COPD increased the subsequent mortality risk.20
Multiple studies on long-term mortality in nonhospitalized 
patients are available. A study from Japan that followed a 
cohort of patients with COPD found that 5-year mortality 
was 27%. Of the 183 patients in the study, 42 patients (23%) 
had FEV
1
 greater than 50% of the predicted value, 59 patients 
(32%) had FEV
1
 35% to 49% of the predicted value, and 
82 patients (45%) had FEV
1
 less than 35% of the predicted 
value.21 One study followed a COPD cohort in a population-
based study for 20 years and found overall mortality of 
54% and 81% for those with severe and very severe COPD 
at entry.22 In a follow-up over 22 years of a large general 
population cohort of 923 cases of COPD found an overall 
mortality of 44% and severe COPD in 71%.23 A study that 
examined the predictive role of frailty on long-term mortality 
(12 years) in elderly subjects with and without COPD found 
that mortality was 48.1% in non-COPD patients and 60.7% in 
COPD patients.24 Overall studies on hospitalized patients with 
AECOPD show higher long-term mortality than population 
studies, which probably reflect differences in disease charac-
teristics between the groups of patients studied. One of these 
characteristics may be susceptibility to exacerbations.25
The findings of low BMI being a risk factor for mortality 
in COPD in the present study has been reported before by 
our group and others.8,18,26 In the present study, there was 
a trend towards a U-shape with the lowest mortality in 
the overweight and a nonsignificant trend towards higher 
mortality in the obese group.
The presence of diabetes mellitus is common among 
patients with COPD.27 The findings in the present study of 
Table 2 Risk factors for death during follow-up in patients with a previous hospital admission for COPD, according to all-cause 
mortality, respiratory mortality, and cardiovascular mortality, respectively
All causes 
HRR (95% CI)
Respiratory death Cardiovascular death
Women 0.77 (0.54–1.10) 0.66 (0.41–1.07) 0.52 (0.18–1.48)
Age 10 years 1.75 (1.40–2.19)* 2.03 (1.47–2.82)* 3.07 (1.80–5.25)*
Current smoker 1.18 (0.78–1.79) 1.57 (0.83–2.82) 0.94 (0.37–2.42)
FEV1 % predicted 0.81 (0.71–0.91)* 0.63 (0.51–0.78)* 0.90 (0.71–1.14)
BMI groups
 ,20 3.21 (1.83–5.60)* 3.99 (1.77–8.99)* 7.82 (1.66–36.8)*
 20–25 1.42 (0.89–2.28) 1.57 (0.76–3.27 1.80 (0.58–5.63)
 25–30 1 1 1
 .30 1.82 (0.95–3.47) 1.68 (0.57–4.97) 3.28 (0.87–12.4)
Cardiovacular disease 1.24 (0.85–1.81) 1.20 (0.69–2.09) 1.98 (0.69–5.72)
Diabetes 3.02 (1.69–5.40)* 4.92 (1.51–16.0)* 5.48 (2.03–14.8)*
SGRQ total score 1.04 (0.99–1.09) 1.00 (0.93–1.08) 1.02 (0.92–1.13)
Note: *P , 0.05.
Abbreviations: HRR, hazard risk ratio; FEV1, forced expiratory volume in 1 second; BMI, body mass index; SGRQ, St George’s Respiratory Questionnaire.
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Figure 3 Distribution of causes of death in COPD patients according to GOLD stage.
Notes: Prespiratory cause of death = 0.002; Pcardiovascular cause of death = 0.02.
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative 
for Chronic Obstructive Pulmonary Disease.
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Figure 2 Kaplan–Meier survival curve in COPD patietns according to GOLD stage.
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative 
for Chronic Obstructive Pulmonary Disease.
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diabetes being a risk factor for long-term mortality in COPD 
confirm our previous findings of short-term mortality.4 
 Mannino et al found that subjects with GOLD stages 3 
or 4 COPD had a higher prevalence of diabetes (OR, 1.5; 
95% CI: 1.9–3.0) and higher risk of hospitalization and 
mortality.28 As expected, diabetes in our study was mostly 
found in COPD patients that were overweight or obese.
The findings of the present study of mortality being 
related to low FEV
1
 and higher GOLD stages is comparable 
to other studies.27,29,30
In the present study, most of the patients died from 
respiratory causes, a result that is similar to other studies.31,32 
In the large TORCH trial, 35% died from pulmonary causes, 
27% from cardiovascular causes, and 21% from cancer.8 
A study from Italy followed 288 patients for 6 years after 
hospitalization for COPD and found that cardiovascular 
diseases were the most common cause of death.18 Eleven 
patients (5%) died from lung cancer in our study. It is 
common for studies to show that a relatively large proportion 
of the patients with COPD die from lung cancer.8,18 This is 
not surprising given that tobacco smoking is a strong risk 
factor for lung cancer, but there are also indications that 
COPD itself is a risk factor for developing lung cancer.33 
Unfortunately, our study did not have the power to evaluate 
a possible inverse association between spirometric GOLD 
stage and death from lung cancer.
There are several strengths of the present study. The 
study was carried out in three countries with similar health 
care systems and represents a broad population of patients. 
It includes a fairly large number of patients, both males and 
females, and none were lost to follow-up regarding time 
of death due to the excellent population registration in the 
Nordic countries. Causes of death are coded in a similar 
fashion in all the Nordic countries. However, there were also 
some weaknesses to our approach: As patients had no regular 
follow up by the study team, the effects of pharmacology 
interventions, pulmonary rehabilitation and other nonphar-
macological interventions being offered to the patients were 
unknown and all these are also potential factors that may affect 
the outcome of the patients. However, the study reflects the 
natural history of COPD subjects being managed under usual 
care in either the primary or higher level. The multicenter 
approach results in different database entries. Causes of 
death were based on death certificates that may not have been 
accurate and we did not get information on causes of death for 
all the patients that were included. It has been suggested that 
relying on the information on death certificates underestimates 
COPD as the cause of death.34 There were also some variables 
that are thought to be important in patients with COPD that 
there was no information on in the current study. It has been 
shown that multidimensional grading systems are better than 
FEV
1
 to predict the risk of death.8 For instance, we had no 
information on physical capability and dyspnea that is often 
a part of such grading systems. This may lead to residual 
confounding. In evaluating the association between treatment 
and mortality, it is important to keep in mind that this was an 
observational study and not a randomized clinical trial.
In conclusion, the present study has clearly demonstrated 
that long-term mortality in patients after hospitalization with 
AECOPD was high and that the risk factors for mortality 
were older age, lower lung function, lower BMI, and diabe-
tes comorbidity. These results should be taken into account 
when making clinical decisions about patients who have 
been admitted to hospital with acute exacerbations. Special 
emphasis should be put on the care of those that have low 
BMI and overweight COPD patients with diabetes.
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